INTELLIA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
INTELLIA THERAPEUTICS, INC. (NTLA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 90.46 thousand shares for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-14.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2018-03-14
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2016-12-31 was 0.00 shares.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2016-09-30 was 0.00 shares.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2017 was 90.46K shares, a 7495.47% increase from fiscal 2016.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2016 was 1.19K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|
| 2017-12-31 | 90.46K shares 10-K · filed 2018-03-14 | |||
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | 0.00 shares derived: sum of 2 quarters · filed 2017-03-14 | 1.19K shares 10-K · filed 2017-03-14 | |
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | 1.19K shares 10-Q · filed 2016-11-01 | ||
| 2016-06-30 | 1.19K shares 10-Q · filed 2016-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |